AB.PA - AB Science S.A.

Paris - Paris Delayed Price. Currency in EUR

AB Science S.A.

3, Avenue George V
Paris 75008
33 1 47 20 00 14

IndustryDrug Manufacturers - Major
Full Time Employees107

Key Executives

NameTitlePayExercisedYear Born
Mr. Alain MoussyCo-Founder, Chairman, CEO & Scientific DirectorN/AN/AN/A
Mr. Denis GicquelDeputy Chief Exec. Officer and Head Pharmacist89kN/AN/A
Mr. Laurent Guy MBAChief Financial OfficerN/AN/AN/A
Dr. Albert Ahn D.V.M.Pres of USA OperationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines. The company's lead compound is the Masitinib, a tyrosine kinase inhibitor, which has completed Phase II trials, as well as in Phase III trials for the treatment of oncology, inflammatory, multiple sclerosis, Alzheimer's, and amyotrophic lateral sclerosis diseases. It also develops other compounds, such as KIT816 for the treatment of mastocytosis, seminoma, and acute myeloid leukemia; and Syk for treating rheumatoid arthritis/B-cell lymphoma. In addition, the company offers Masitinib for the treatment of oncology and inflammatory diseases for dogs and cats. It markets its Masitinib under the Masivet brand in Europe; and Kinavet brand in the United States. The company serves hospitals and specialist physicians. The company was founded in 2001 and is headquartered in Paris, France.

Corporate Governance

AB Science S.A.’s ISS Governance QualityScore as of June 1, 2018 is 10. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.